Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of GH Research in a report released on ...

Cantor Fitzgerald assumed coverage on shares of GH Research (NASDAQ:GHRS – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The firm issued an ...

Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

周四 - Cantor Fitzgerald对GH Research PLC (NASDAQ: GHRS )给予"增持"评级，目标价设定为14.00美元。这一新的评级基于GHRS的GH001（一种吸入式5-MeO-DMT疗法）有望成为难治性抑郁症（TRD）标准疗法的潜力。Cantor ...

Cantor Fitzgerald initiated coverage of GH Research (GHRS) with an Overweight rating and $14 price target Maximize Your Portfolio with Data ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing ...

(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, announced ...

On Monday, H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently trading at $8.83, the stock sits well... DUBLIN - GH ...